Local CTLA4Ig synergizes with one-dose anti-LFA-1 to achieve long-term acceptance of pancreatic islet allografts.
Chahine
A A
AA
Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine 19104.
Yu
M
M
McKernan
M
M
Stoeckert
C
C
Linsley
P S
PS
Lau
H T
HT
D000069594:Abatacept; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000008:administration & dosage / Q000096:biosynthesis / Q000627:therapeutic use*; D060908:CTLA-4 Antigen; D003921:Diabetes Mellitus, Experimental / Q000628:therapy*; D004357:Drug Synergism; D006085:Graft Survival / Q000276:immunology*; D018796:Immunoconjugates; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D016169:Lymphocyte Function-Associated Antigen-1 / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009132:Muscles; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000096:biosynthesis / Q000627:therapeutic use; D014162:Transfection
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556707:Ctla4 protein, mouse; D018796:Immunoconjugates; D016169:Lymphocyte Function-Associated Antigen-1; D011994:Recombinant Proteins; D000069594:Abatacept